You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
Name1,10-Phenanthroline
Accession NumberDB02365  (EXPT02592)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIW4X6ZO7939
CAS number66-71-7
WeightAverage: 180.2053
Monoisotopic: 180.068748266
Chemical FormulaC12H8N2
InChI KeyDGEZNRSVGBDHLK-UHFFFAOYSA-N
InChI
InChI=1S/C12H8N2/c1-3-9-5-6-10-4-2-8-14-12(10)11(9)13-7-1/h1-8H
IUPAC Name
1,10-phenanthroline
SMILES
C1=CC2=CC=C3C=CC=NC3=C2N=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Methyl-accepting chemotaxis protein IIProteinunknownNot AvailableSalmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)P02941 details
Metallo-beta-lactamase L1ProteinunknownNot AvailablePseudomonas maltophiliaP52700 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with 1,10-Phenanthroline.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with 1,10-Phenanthroline.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with 1,10-Phenanthroline.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with 1,10-Phenanthroline.Experimental, Illicit
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with 1,10-Phenanthroline.Approved, Investigational
Acebutolol1,10-Phenanthroline may increase the bradycardic activities of Acebutolol.Approved
AcetylcholineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Acetylcholine.Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with 1,10-Phenanthroline.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with 1,10-Phenanthroline.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with 1,10-Phenanthroline.Experimental
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with 1,10-Phenanthroline.Approved, Illicit, Investigational
Alprenolol1,10-Phenanthroline may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with 1,10-Phenanthroline.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with 1,10-Phenanthroline.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with 1,10-Phenanthroline.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with 1,10-Phenanthroline.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with 1,10-Phenanthroline.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with 1,10-Phenanthroline.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with 1,10-Phenanthroline.Approved
Aop2007041,10-Phenanthroline may increase the bradycardic activities of Aop200704.Investigational
ArecolineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Arecoline.Experimental
Arotinolol1,10-Phenanthroline may increase the bradycardic activities of Arotinolol.Approved
Atenolol1,10-Phenanthroline may increase the bradycardic activities of Atenolol.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with 1,10-Phenanthroline.Approved
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with 1,10-Phenanthroline.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Vet Approved
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with 1,10-Phenanthroline.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with 1,10-Phenanthroline.Approved, Investigational
Befunolol1,10-Phenanthroline may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with 1,10-Phenanthroline.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with 1,10-Phenanthroline.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with 1,10-Phenanthroline.Approved, Vet Approved
Betaxolol1,10-Phenanthroline may increase the bradycardic activities of Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Bethanechol.Approved
Bevantolol1,10-Phenanthroline may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with 1,10-Phenanthroline.Approved
Bisoprolol1,10-Phenanthroline may increase the bradycardic activities of Bisoprolol.Approved
BoceprevirThe serum concentration of 1,10-Phenanthroline can be decreased when it is combined with Boceprevir.Approved
Bopindolol1,10-Phenanthroline may increase the bradycardic activities of Bopindolol.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational
Bucindolol1,10-Phenanthroline may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with 1,10-Phenanthroline.Approved
Bufuralol1,10-Phenanthroline may increase the bradycardic activities of Bufuralol.Experimental, Investigational
Bupranolol1,10-Phenanthroline may increase the bradycardic activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with 1,10-Phenanthroline.Approved
CarbacholThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Carbachol.Approved
CarbamazepineThe metabolism of 1,10-Phenanthroline can be increased when combined with Carbamazepine.Approved, Investigational
Carteolol1,10-Phenanthroline may increase the bradycardic activities of Carteolol.Approved
Carvedilol1,10-Phenanthroline may increase the bradycardic activities of Carvedilol.Approved, Investigational
Celiprolol1,10-Phenanthroline may increase the bradycardic activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Cevimeline.Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with 1,10-Phenanthroline.Withdrawn
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with 1,10-Phenanthroline.Withdrawn
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with 1,10-Phenanthroline.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with 1,10-Phenanthroline.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with 1,10-Phenanthroline.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with 1,10-Phenanthroline.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with 1,10-Phenanthroline.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with 1,10-Phenanthroline.Approved, Vet Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with 1,10-Phenanthroline.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with 1,10-Phenanthroline.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with 1,10-Phenanthroline.Approved
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with 1,10-Phenanthroline.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational, Vet Approved
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with 1,10-Phenanthroline.Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with 1,10-Phenanthroline.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with 1,10-Phenanthroline.Approved
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with 1,10-Phenanthroline.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with 1,10-Phenanthroline.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with 1,10-Phenanthroline.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with 1,10-Phenanthroline.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with 1,10-Phenanthroline.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with 1,10-Phenanthroline.Withdrawn
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with 1,10-Phenanthroline.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with 1,10-Phenanthroline.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with 1,10-Phenanthroline.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with 1,10-Phenanthroline.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with 1,10-Phenanthroline.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with 1,10-Phenanthroline.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with 1,10-Phenanthroline.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with 1,10-Phenanthroline.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with 1,10-Phenanthroline.Approved
DipyridamoleThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Dipyridamole.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with 1,10-Phenanthroline.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with 1,10-Phenanthroline.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with 1,10-Phenanthroline.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational
EPIBATIDINEThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with EPIBATIDINE.Experimental
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with 1,10-Phenanthroline.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with 1,10-Phenanthroline.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with 1,10-Phenanthroline.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with 1,10-Phenanthroline.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with 1,10-Phenanthroline.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with 1,10-Phenanthroline.Investigational
Esmolol1,10-Phenanthroline may increase the bradycardic activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with 1,10-Phenanthroline.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with 1,10-Phenanthroline.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with 1,10-Phenanthroline.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with 1,10-Phenanthroline.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with 1,10-Phenanthroline.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with 1,10-Phenanthroline.Approved
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with 1,10-Phenanthroline.Approved
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with 1,10-Phenanthroline.Approved
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with 1,10-Phenanthroline.Approved
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with 1,10-Phenanthroline.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with 1,10-Phenanthroline.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with 1,10-Phenanthroline.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with 1,10-Phenanthroline.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with 1,10-Phenanthroline.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with 1,10-Phenanthroline.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with 1,10-Phenanthroline.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with 1,10-Phenanthroline.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with 1,10-Phenanthroline.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with 1,10-Phenanthroline.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with 1,10-Phenanthroline.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with 1,10-Phenanthroline.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with 1,10-Phenanthroline.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with 1,10-Phenanthroline.Approved, Investigational, Withdrawn
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with 1,10-Phenanthroline.Approved
GarlicThe serum concentration of 1,10-Phenanthroline can be decreased when it is combined with Garlic.Approved
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational, Vet Approved
GTS-21The risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with GTS-21.Investigational
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with 1,10-Phenanthroline.Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with 1,10-Phenanthroline.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with 1,10-Phenanthroline.Withdrawn
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with 1,10-Phenanthroline.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with 1,10-Phenanthroline.Approved, Vet Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with 1,10-Phenanthroline.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with 1,10-Phenanthroline.Approved
Indenolol1,10-Phenanthroline may increase the bradycardic activities of Indenolol.Withdrawn
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with 1,10-Phenanthroline.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with 1,10-Phenanthroline.Investigational
Labetalol1,10-Phenanthroline may increase the bradycardic activities of Labetalol.Approved
Levobunolol1,10-Phenanthroline may increase the bradycardic activities of Levobunolol.Approved
LobelineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Lobeline.Investigational
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with 1,10-Phenanthroline.Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with 1,10-Phenanthroline.Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with 1,10-Phenanthroline.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with 1,10-Phenanthroline.Vet Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with 1,10-Phenanthroline.Approved
MethacholineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Methacholine.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with 1,10-Phenanthroline.Experimental
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with 1,10-Phenanthroline.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with 1,10-Phenanthroline.Approved, Vet Approved
Metipranolol1,10-Phenanthroline may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with 1,10-Phenanthroline.Approved
Metoprolol1,10-Phenanthroline may increase the bradycardic activities of Metoprolol.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with 1,10-Phenanthroline.Approved, Illicit
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with 1,10-Phenanthroline.Approved
Mivacurium1,10-Phenanthroline may decrease the neuromuscular blocking activities of Mivacurium.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with 1,10-Phenanthroline.Approved, Vet Approved
N-butylscopolammonium bromideThe therapeutic efficacy of N-butylscopolammonium bromide can be decreased when used in combination with 1,10-Phenanthroline.Vet Approved
Nadolol1,10-Phenanthroline may increase the bradycardic activities of Nadolol.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with 1,10-Phenanthroline.Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with 1,10-Phenanthroline.Approved, Withdrawn
NicotineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Nicotine bitartrate.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with 1,10-Phenanthroline.Approved
NVA237The therapeutic efficacy of NVA237 can be decreased when used in combination with 1,10-Phenanthroline.Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with 1,10-Phenanthroline.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with 1,10-Phenanthroline.Investigational
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with 1,10-Phenanthroline.Approved
Oxprenolol1,10-Phenanthroline may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with 1,10-Phenanthroline.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with 1,10-Phenanthroline.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with 1,10-Phenanthroline.Approved
Penbutolol1,10-Phenanthroline may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with 1,10-Phenanthroline.Approved
PethidineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Pethidine.Approved
PilocarpineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Pilocarpine.Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with 1,10-Phenanthroline.Approved
Pindolol1,10-Phenanthroline may increase the bradycardic activities of Pindolol.Approved
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with 1,10-Phenanthroline.Approved
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with 1,10-Phenanthroline.Approved
Practolol1,10-Phenanthroline may increase the bradycardic activities of Practolol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with 1,10-Phenanthroline.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with 1,10-Phenanthroline.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with 1,10-Phenanthroline.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with 1,10-Phenanthroline.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with 1,10-Phenanthroline.Experimental
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with 1,10-Phenanthroline.Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with 1,10-Phenanthroline.Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with 1,10-Phenanthroline.Investigational
Propranolol1,10-Phenanthroline may increase the bradycardic activities of Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with 1,10-Phenanthroline.Approved
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with 1,10-Phenanthroline.Approved
Rapacuronium1,10-Phenanthroline may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with 1,10-Phenanthroline.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with 1,10-Phenanthroline.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with 1,10-Phenanthroline.Approved
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with 1,10-Phenanthroline.Approved
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with 1,10-Phenanthroline.Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with 1,10-Phenanthroline.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with 1,10-Phenanthroline.Approved
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with 1,10-Phenanthroline.Approved
Sotalol1,10-Phenanthroline may increase the bradycardic activities of Sotalol.Approved
St. John's WortThe metabolism of 1,10-Phenanthroline can be increased when combined with St. John's Wort.Nutraceutical
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with 1,10-Phenanthroline.Approved
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with 1,10-Phenanthroline.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with 1,10-Phenanthroline.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Temsirolimus.Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with 1,10-Phenanthroline.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with 1,10-Phenanthroline.Approved
Timolol1,10-Phenanthroline may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with 1,10-Phenanthroline.Approved
TipranavirThe serum concentration of 1,10-Phenanthroline can be decreased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with 1,10-Phenanthroline.Approved
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with 1,10-Phenanthroline.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with 1,10-Phenanthroline.Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with 1,10-Phenanthroline.Approved
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with 1,10-Phenanthroline.Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with 1,10-Phenanthroline.Approved
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with 1,10-Phenanthroline.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with 1,10-Phenanthroline.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with 1,10-Phenanthroline.Approved
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with 1,10-Phenanthroline.Approved
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with 1,10-Phenanthroline.Approved, Investigational
VareniclineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with 1,10-Phenanthroline.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with 1,10-Phenanthroline.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with 1,10-Phenanthroline.Approved
Food InteractionsNot Available
References
Synthesis Reference

Judith N. Burstyn, Omar Green, Bhavesh A. Gandhi, “BISCOPPER COMPLEXES, METHODS OF SYNTHESIS, AND USES THEROF.” U.S. Patent US20080206890, issued August 28, 2008.

US20080206890
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9879
Blood Brain Barrier+0.9825
Caco-2 permeable-0.5136
P-glycoprotein substrateNon-substrate0.6487
P-glycoprotein inhibitor INon-inhibitor0.8831
P-glycoprotein inhibitor IINon-inhibitor0.9805
Renal organic cation transporterNon-inhibitor0.7775
CYP450 2C9 substrateNon-substrate0.866
CYP450 2D6 substrateNon-substrate0.8486
CYP450 3A4 substrateNon-substrate0.7961
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6111
Ames testAMES toxic0.8512
CarcinogenicityNon-carcinogens0.9476
BiodegradationNot ready biodegradable0.9838
Rat acute toxicity2.1323 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9681
hERG inhibition (predictor II)Non-inhibitor0.8708
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point117 °CPhysProp
boiling point> 300 °CPhysProp
water solubility2690 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.78HANSCH,C ET AL. (1995)
pKa4.27 (at 20 °C)ALBERT,A ET AL. (1948)
Predicted Properties
PropertyValueSource
Water Solubility0.132 mg/mLALOGPS
logP2.31ALOGPS
logP2.29ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area25.78 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity53.9 m3·mol-1ChemAxon
Polarizability19.26 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-001i-1900000000-e3edab983e41e183110aView in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenanthrolines. These are aromatic polycyclic compounds containing the phenanthroline skeleton, which is a derivative of phenanthrene, and consists of two pyridine rings non-linearly joined by a benzene ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPhenanthrolines
Sub ClassNot Available
Direct ParentPhenanthrolines
Alternative Parents
Substituents
  • 1,10-phenanthroline
  • Quinoline
  • Benzenoid
  • Pyridine
  • Heteroaromatic compound
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)
Pharmacological action
unknown
General Function:
Transmembrane signaling receptor activity
Specific Function:
Receptor for the attractant L-aspartate and related amino and dicarboxylic acids. Tar mediates taxis away from the repellents cobalt and nickel. Unlike in E.coli tar, it does not mediates maltose taxis.Chemotactic-signal transducers respond to changes in the concentration of attractants and repellents in the environment, transduce a signal from the outside to the inside of the cell, and facilit...
Gene Name:
tar
Uniprot ID:
P02941
Molecular Weight:
59613.55 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Pseudomonas maltophilia
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Has a high activity against imipenem.
Gene Name:
Not Available
Uniprot ID:
P52700
Molecular Weight:
30800.635 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23